52
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Effect of 1,25(OH)2 Vitamin D3 Analogs on Differentiation Induction and Cytokine Modulation in Blasts from Acute Myeloid Leukemia Patients

&
Pages 2119-2126 | Received 03 Oct 2003, Published online: 03 Aug 2009

References

  • Tenen, D.G. (2003) "Disruption of differentiation in human cancer: AML shows the way", Nature Reviews, 3, 89 — 101.
  • Gattei, V., Degan, M., Aldinucci, D., De Tullis, A., Rossi, F.M., Mazzocco, F.T., et al. (1998) "Differential expression of the RET gene in human acute myeloid leukemia", Annals of Hematology, 77(5), 207 — 210.
  • Lococo, F., Zelant, A., Kimchi, A., Carducci, M., Gore, S.D. and Waxman, S. (2002) "Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond", Cancer Research, 62, 5618 — 5621.
  • Mauro, M.J. and Druker, B.J. (2001) "STI-571: Targeting BCR-ABL as therapy for CML", The Oncologist, 6, 233–238.
  • Elstner, E., Lee, Y.Y., Hashiya, M., Pakkala, S., Binderup, L., Norman, A.W., et al. (1994) "1a, 25-Dihydroxy-20-epi- Vitamin D3: An extraordinary potent inhibitor of leukemic cell growth in vitro", Blood, 84, 1960–1967.
  • Guzey, M., Kitada, S. and Reed, J.C. (2002) "Apoptosis induction by 1, 25- Dihydroxyvitamin D3 in prostate cancer", Molecular Cancer Therapeutics, 1, 667–677.
  • Hansen, CM., Hansen, D., Holm, P.K. and Binderup, L. (2001) "Vitamin D compounds exert anti-apoptotic effects in human osteocarcinoma cells in vitro", Journal of Steroid Biochemistry and Molecular Biology, 77, 1–11.
  • Hershberger, P.A., Modzelewslci, R.A., Shurin, Z.R., Reueger, R.M., Trump, D.L. and Johnson, CS. (1999) "1, 25-Dihydroxy-cholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down modulates p21(Waf licip 1) in vitro and in vivo", Cancer Research, 59, 2644–2649.
  • Hisatake, J., O'Kelly, J., Uskokovic, M.R., Tomoyasu, S. and Koeffler, H.P. (2001) "Novel Vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentia-tion, apoptosis, cell cycle, and induction of PTEN in leukemic cells", Blood, 97, 2427 — 2433.
  • Jensen, S.S., Winkel, MM., Lukas, J., Binderup, L. and Bartek, J. (2001) "Inhibitory effects of 1a-25-Dihydroxyvitamin D3 on the GI-S phase-controlling machinery", Molecular Endocrinology, 15, 1370— 1380.
  • Miller, G.J., Stapleton, G.E., Hedlund, T.E. and Moffat, K.A. (1995) "Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1, 25-Dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines", Clinical Cancer Research, 1, 997–1003.
  • Srivastava, M.D., Ambrus, J.L. and Uskokovic, M.R. (1995) "Calcitriol analogs cause differentiation of neoplastic cells in culture", Research Communications in Molecular Pathology and Pharmacology, 88, 77–85.
  • Srivastava, M.D., DeLuca, H.F. and Ambrus, J.L. (1994) "Differ-entiation of neoplastic cells toward normal induced by Vitamin D3 derivatives", Research Communications in Chemical Pathology and Pharmacology, 83, 115 — 123.
  • Jung, S.J., Lee, Y.Y., Pakkala, S., Devos, E., Elstner, E., Norman, A.W., et al. (1994) "1,25(OH)2-16 ene-Vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia", Leukemia Research, 18, 453–463.
  • Zhou, J.Y., Norman, A.W., Lubert, M., Collins, ED., Uskokovic, M.R. and Koeffler, H.P. (1989) "Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect of either intestinal calcium absorption or bone calcium mobilization", Blood, 74, 82–93.
  • Adorini, L. (2002) "Immunomodulatory effects of Vitamin D receptor ligands in autoimmune diseases", International Immuno-pharmacology, 2, 1017 — 1028.
  • Berry, D., Clark, C.S. and Meckling-Gill, K.A. (2002) "la, 25-Dihydroxyvitamin D3 stimulates phosphorylation of IKBa and synergizes with TPA to induce nuclear translocation of NFKB during monocytic differentiation of NB4 leukemia cells", Experi-mental Cell Research, 272, 176 — 184.
  • Srivastava, M.D. (1995) Modulation of proinflammatory cytolcine production by human hematopoietic cell lines. Ph.D. Thesis, State University of New York at Buffalo, USA 1995.
  • Srivastava, M.D., DeLuca, H.F. and Ambrus, J.L. (1994) "Inhibi-tion of IL-6 and IL-8 produciton in human fibroblast cell lines by 1,25(OH)2 Vitamin D3 and two of its analogs with lower calcemic activity", Research Communications in Chemical Pathology and Pharmacology, 83, 145–150.
  • Behringer, D., Schaufler, J., Kresin, V., Lubbert, M. and Lindemann, A. (2001) "Differentiation associated modulation of the cytolcine and chemolcine expression pattern in human myeloid cell lines", Leukemia Research, 25, 141–149.
  • D'Ambrosio, D., Cippitelli, M., Cocciolo, M.G., Mazzeo, D., DiLucia, P., Lang, R., et al. (1998) "Inhibition of IL-12 production by 1,25-Dihydroxyvitamin D3. Involvement of NF-KB down regulation in transcriptional repression of the p40 gene", Journal of Clinical Investigation, 101, 252— 262.
  • Harant, H., Andrew, P.J., Reddy, G.S., Foglar, E. and Lindley, LI (1997) "1-alpha,25-Dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-Kappa B mediated interleulcin-8 gene expression", European Journal of Biochemistry, 250, 63–71.
  • Kang, S., Griffiths, CE., Fancher, L., Hamilton, T.A. and Choi, J.H. (1998) "Calcipotriene-induced improvement in psoriasis is associated with reduced interleulcin-8 and increased interleulcin-10 levels within lesions", British Journal of Dermatology, 138, 77–83.
  • Masood, R., Nagpal, S., Zheng, T., Cai, J., Tulpule, A., Smith, DL., et al. (2000) "Kaposi's sarcoma is a therapeutic target for Vitamin D3 receptor agonist", Blood, 96, 3188–3194.
  • Muller, K., Haahr, P.M., Diamant, M., Rieneck, K., Kharazmi, A. and Bendtzen, K. (1992) "1,25,dihydroxyvitamin D3 inhibits cytolcine production by human blood monocytes at the post-transcriptional level", Cytokine, 4, 506 — 512.
  • Reichel, H., Koeffler, H.P., Tobler, A. and Norman, A.W. (1987) "1-alpha, 25-dihydroxyvitamin D3 inhibits gamma interferon synthesis by normal human peripheral blood lumphocytes", Proceedings of the National Academy of Science, 84, 3385–3390.
  • Zhang, J.Z., Maruyama, K., Ono, I., Iwatsulci, K. and Kaneko, F. (1994) "Regulatory effects of 1,25,dihydroxyvitamin D3 and a novel Vitamin D3 analog MC903 on secretion of interleulcin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1)", Journal of Dermato-logic Science, 7, 24–31.
  • Yamada, S., Shimizu, M. and Yamamoto, K. (2003) "Structure — function relationships of Vitamin D including ligand recognition by the Vitamin D receptor", Medical Research Reviews, 23, 89–115.
  • Li, C., Wang, Y., Gao, L., Zhang, J., Shao, J., Wang, S., et al. (2002) "Expression of Toll-like receptors 2 and 4 and CD14 during differentiation of HL-60 cells induced by phorbol 12-myristate 13-acetate and la, 25-dihydroxy-Vitamin D3", Cell Growth and Differentiation, 13, 27–38.
  • Danilenko, M., Wang, X. and Studzinslci, G.P. (2001) "Carsonic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents", Journal of the National Cancer Institute, 93, 1224— 1233.
  • Funatolci, M., Miyazawa, F.K., Yaguchi, M., Gotoh, A. and Ohyashilci, K. (2002) "Combination of 22-0XA-1, 25-dihydrox-yvitamin D3, a Vitamin D3 derivative, with Vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2 — inducing apoptosis in HL-60 cells", Leukemia, 16, 1519–1527.
  • Gullberg, U., Nilsson, E., Einhorn, E. and Olsson, I. (1985) "Combinations of interferon gamma and retinoic acid or 1-alpha, 25-dihydroxychole-calciferol induce differentiation of the human monoblast leukemia cell line U-937", Experimental Hematology, 13, 675— 679.
  • Nakagawa, K., Sowa, Y., Kurobe, M., Ozono, K., Caldera, M.L.S., Reddy, G.S., et al. (2001) "Differential activities of la,25-dihydroxy-16-ene-Vitamin D3 analogs and their 3-epimers on human promyelocytic leukemia (HL-60) cell differentiation and apoptosis", Steroids, 66, 327–337.
  • Nhtsu, N., Hayashi, Y., Sugita, K. and Honma, Y. (2001) "Sensitization by 5-aza-21-deoxycytidine of leukemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and la, 25-dihydroxyvitamin D3", British Journal of Haematology, 112, 315–326.
  • Norman, A.W., Zhou, J.Y., Henry, H.L., Uskokovic, M.R. and Koeffler, H.P. (1990) "Structure function studies on analogues of la,25-dihydroxy-vitamin D3: Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption", Cancer Research, 50, 6857 — 6864.
  • Savli, H., Aslto, Y., Nagy, B., Knuvtila, S. and Pakkala, S. (2002) "Gene expression analysis of 1, 25(OH)2 D3 dependent differentia-tion of HL-60 cells: a cDNA array study", British Journal of Haematology, 118, 1065 — 1070.
  • Tagliafico, E., Tenedini, E., Bergamaschi, A., Manfredini, R., Percudani, R., Siena, M., et al. (2002) "Gene expression profile of Vitamin D3 treated HL-60 cells shows an incomplete molecular phenotypic conversion to monocytes", Cell Death and Differentia-tion, 9, 1185–1195.
  • Trayner, ID., Bustorff, T., Etches, A.E., Mufti, G.J., Foss, Y. and Farzaneh, F. (1998) "Changes in antigen expression on differentiat-ing HL-60 cells treated with dimethylsulphoxide, all-trans retinoic acid, al, 25-dihydroxy-vitamin D3 or 12-0-tetradecanoylphorbol-13-acetate", Leukemia Research, 22, 537— 547.
  • Yamada, K., Honma, Y., Asahi, K.I., Sassa, T., Hino, K.I. and Tomoyasu, S. (2001) "Differentiation of human acute myeloid leukemia cells in primary culture in response to cotylenin A, a plant growth regulator", British Journal of Haematology, 114, 814–821.
  • Scheper, R.J., Butte, J.W.M., Brakkee, J.G.P., Quak, J.J., Van der Schoot, E., Balm, A.J.M., et al. (1988) "Monoclonal antibody JSB-1 detects a highly conserved epitope on the p-glycoprotein associated with multi-drug resistance", International Journal of Cancer, 42, 389— 394.
  • Al-alami, O., Sammons, J., Martin, J.H. and Hassan, H.T. (1998) "Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U-937 CD34 negative human leukemia cells", Leukemia Research, 22, 939–945.
  • Srivastava, M.D., Ambrus, J.L. and Srivastava, B.I.S. (1998) Cytolcine production by normal and malignant human cell lines. In Proceedings of the 17th International Cancer Congress Rio de Janeiro, 1998, edited by M. Morales, R. Brentani and R. Bevilacqua. Pp 115–118. Bologna (Italy): Monduzzi Editions SPA.
  • Honma, Y. and Ishii, Y. (2002) "Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones", Leukemia and Lymphoma, 43(9), 1729— 1735.
  • Bruserud, O. and Gjertsen, B.T. (2000) "New strategies for the treatment of acute myelogenous leukemia: differentiation induc-tion—present use and future possibilities", Stem Cells, 18(3), 157 — 165.
  • Olsson, I., Bergh, G., Ehinger, M. and Gullberg, U. (1996) "Cell differentiation in acute myeloid leukemia", European Journal of Haematology, 57(1), 1–16.
  • Paul, C.C., Aly, E., Lehman, JA., Page, S.M., Gomez-Cambronero, J., Ackerman, Si., et al. (2000) "Human cell line that differentiates to all myeloid lineages and expresses neutrophil secondary granule genes", Experimental Hematology, 28(12), 1373— 1380.
  • Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., et al. (1996) "A central role for Stat3 in IL-6 induced regulation of growth and differentiation in M1 leukemia cells", EMBO Journal, 15(14), 3651–3658.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.